1Xie L, Zhai H, Shi W.Penetrating keratoplasty for corneal perforations in fungal keratitis[J].Cornea,2007,26(2) : 158-162.
2Xie L, Zhai H, Zhao J, et al.Antifungal Susceptibility for Common Pathogens of Fungal Keratitis in Shandong Province, China[J].American Journal of Ophthalmology, 2008,146(2 ) : 260-265.
3Li L, Wang Z, Li R, et al.ln Vitro Evaluation of Combination Antifungal Activity against Fusarium Species Isolated from Ocular Tissues of Keratomycosis Patients [J].American Journal of Ophthalmology, 2008,146( 5 ) : 724-728.
4Thiel M A, Zinkernagel A S, Burhenne J, et al.Voriconazole concentration in human aqueous humor and plasma during topical or combined topical and systemic administration for fungal keratitis [J]. Antimicrobial agents and chemotherapy, 2007,51 ( 1 ) : 239.
5Hariprasad S M, Mieler W F, Holz E R, et al.Deterrnination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans[Z].Arn Med Assoc, 2004.122,42-47.
6Bunya V Y, Hammersmith K M, Rapuano C J, et al.Topical and oral voriconazole in the treatment of fungal keratitis [J].American journal of ophthalmology,2007,143( 1 ): 151-153.
7Giaconi J A, Marangon F B, Miller D, et al.Voriconazole and fungal keratitis : a report of two treatment failures [J].Joumal of Ocular Pharmacology & Therapeutics, 2006,22(6) : 437-439.
8Kernt M, Kampik A.lntracameral voriconazole: In vitro safety for human ocular cells[J].Toxicology, 2009,258 ( 2-3 ) : 84-93.
9Torres H A, Hachem R Y, Chemaly R F, et al.Posaconazole: a broad-spectrum triazole antifungal [J].The Lancet Infectious Diseases, 2005,5(12) :775-785.
10Schiller D S, Fung H B.Posaconazole: an extended-spectrum triazole antifungal agent[J].Clinical Therapeutics, 2007,29(9 ) : 1862-1886.
3Gallis HA, Drew RH, Pickard, WW. Amphotericin B : 30 years of clinical experience[J]. Rev Infect Dis, 1990,12:308 - 329.
4Lockman PR, Mumper R J, Khan MA, et al. Nanoparticle technology for drug delivery across the blood-brain barrier[J]. Drug Dev Ind Pharm, 2002,28(1) : 1 - 13.
5Kuo YC, Chen HH. Effect of nanoparticulate polybutylcyanoacrylate and methylmethacrylate-sulfopropylmethacrylate on the permeability of zidovudine and tamivudine across the in vitro blood-brain barrier [J]. Int J Pharm. 2006,327(1 -2):160- 169.
6Kuo YC, Su FL. Transport of stavudine, delavirdine, and saquinavir across the blood-brain barrier by polybutylcyanoacrylate, methylmethacrylate-sulfopropylmethacrylate, and solid lipid nanoparticles[J]. Int J Pharm, 2007,340(1 -2):143 - 152.
7Carl VC, David AS. Comparative effieacies of four amphotericin B formulations-Fungizone, Amphotec (amphocil), AmBisome, and Abelcet-against systemic murine aspergillosis [ J]. Antimicrobial Agents and Chemotherapy, 2004, 48(3):1047- 1050.
8Sandeep S, Junaid AK, Prahlad CG. Toxicity and therapeutic efficacy of amphotericin B delivered through cholesterol hemisuccinate vesicles in the treatment of experimental murine aspergillosis [ J ]. Journal of Antimicrobial Chemotherapy, 1998, 42 : 635 - 642.
